Making the top three cancer drugs in 2018 is Avastin (bevacizumab), taking another spot in Roche’s star portfolio of blockbuster oncology drugs.  The monoclonal antibody drug works by reducing the supply of oxygen and nutrients to a tumor and preventing the growth of new blood vessels. Contributing to its success is its ability to treat a variety of cancers including kidney, cervical, ovarian and brain tumors.

You cannot copy content of this page